The presence of TP53 mutations and coexisting complex karyotype in patients with MDS may lead to reduced overall survival (OS) due to increased relapse rates,12 but this has not been replicated in other large studies.13 The gene discussed is TP53; the disease is myelodysplastic syndrome.